Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
SUMMARY Tuberous sclerosis complex (TSC) is a dominantly inherited disease with high penetrance and morbidity, and is caused by mutations in either of two genes, TSC1 or TSC2. Most affected individuals display severe neurological manifestations - such as intractable epilepsy, mental retardation and...
Saved in:
Main Authors: | Laura Magri (Author), Manuela Cominelli (Author), Marco Cambiaghi (Author), Marco Cursi (Author), Letizia Leocani (Author), Fabio Minicucci (Author), Pietro Luigi Poliani (Author), Rossella Galli (Author) |
---|---|
Format: | Book |
Published: |
The Company of Biologists,
2013-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
mTOR Inhibition and Tuberous Sclerosis Prevention
by: J Gordon Millichap
Published: (2013) -
Case Report: Tuberous sclerosis complex-associated hemihypertrophy successfully treated with mTOR inhibitor sirolimus
by: Konomi Shimoda, et al.
Published: (2024) -
Tuberous sclerosis
by: Anisha George, et al.
Published: (2015) -
Tuberous Sclerosis
by: K. N. Monahov, et al.
Published: (2018) -
Tuberous Sclerosis
by: J Gordon Millichap
Published: (1988)